Jess Moerland
Employment
Postdoctoral fellow, Indiana University Indianapolis, Indianapolis, 2025 - Present
Publications
Synthetic Oleanane Triterpenoids Reduce Tumor Growth and Promote an Anti-Tumor Immune Response Independent of Cancer KEAP1 Mutational Status Antioxidants (2025)
Synthetic Oleanane Triterpenoids Reduce Tumor Growth and Promote an Anti-Tumor Immune Response Independent of Cancer KEAP1 Mutational Status Antioxidants (2025)
The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model Cancers (2025)
The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis Molecules and Cells (2023)
The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner Antioxidants (2023)
The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer Scientific Reports (2022)
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer Cancers (2021)
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice Scientific Reports (2021)
Potential therapeutic uses of rexinoids Advances in Immunopharmacology (2021)
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer Scientific Reports (2020)
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models npj Breast Cancer (2019)
